Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

N/ACompletedNCT01198899

University Hospital, Ghent540 enrolled

Overview

The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study

Study Type

OBSERVATIONAL

Enrollment

540

Conditions

Left Ventricular Hypertrophy

Interventions

blood samplingOTHER

Blood sampling will be used.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients over 18 years undergoing a routine echocardiography in the participating hospitals * Both genders will be considered. * Patients can be included if on 2D echocardiography the maximal septal wall thickness \> 13 mm and/or the posterior wall thickness \> 13 mm. The limit for inclusion is kept relatively low to detect early forms of Fabry cardiomyopathy.

Locations (9)

AZ Imelda

Bonheiden, Belgium

AZ Sint-Blasius

Dendermonde, Belgium

AZ Sint-Lucas

Ghent, Belgium

Maria Middelares

Ghent, Belgium

Outcomes

Primary Outcomes

Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography

patients with left ventricular hypertrophy will be screened for Fabry mutations, and results will be communicated within four months

Time frame: At baseline T0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.